AYTU BioPharma (AYTU) Stock: Buy, Sell, or Hold?
AYTU - AYTU BioPharma, Inc. Common Stock
$1.99
-0.06 (-2.93%)
▼
5d:
-12.91%
30d:
-15.68%
90d:
-9.13%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Sep 22, 2026
7d
Get Alerted When AYTU Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: AYTU is down 12.9% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: AYTU is down 12.9% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: AYTU is currently trading at $1.99, which is considered oversold relative to its 30-day fair value range of $2.18 to $2.38. From a valuation perspective, the stock is trading at a discount (Forward PE: -26.5) compared to its historical average (14.8). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, AYTU is in a downtrend. The price is currently testing key support at $1.99. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: AYTU scores 29/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $9.50 (+377.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, AYTU is in a downtrend. The price is currently testing key support at $1.99. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: AYTU scores 29/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $9.50 (+377.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$2.18 -
$2.38
Company Quality Score
41/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
61.9%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (29/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 377.4% below Wall St target ($9.50)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- WARNING: Composite score 41/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$2.18 -
$2.38
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$1.99
Resistance Level
$2.39
Current Trend
Downtrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-26.53
Wall Street Target
$9.50
(+377.4%)
Revenue Growth (YoY)
-32.7%
Profit Margin
-60.2%
PE vs Historical
-26.5 vs 14.8
CHEAP
Share & Embed Analysis
Last updated: September 14, 2026 3:56 AM ET
Data refreshes hourly during market hours. Next update: 4:56 AM
Data refreshes hourly during market hours. Next update: 4:56 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is AYTU showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$211 | 60 HOLD |
|
LQDA
Liquidia Technologies Inc |
STRONG BUY
10 analysts |
$108 | 70 BUY |
|
INDV
Indivior PLC Ordinary Sh… |
STRONG BUY
7 analysts |
$49 | 69 BUY |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$108 | 46 HOLD |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$664 | 47 HOLD |
